|
Dec 27
|
Gracell downgrade, Fusion upgrade: Wall Street's top analyst calls
|
|
Dec 27
|
AstraZeneca (AZN) Set to Acquire Gracell for $1.2 Billion
|
|
Dec 26
|
These Stocks Moved the Most Today: RayzeBio, Gracell, NIO, Intel, Manchester United, FedEx, Arm, and More
|
|
Dec 26
|
US STOCKS-Wall Street ends higher in final stretch of 2023, rate cuts in view
|
|
Dec 26
|
AstraZeneca to Acquire Gracell in $1.2 Billion Deal to Further Cell Therapy Goals
|
|
Dec 26
|
AstraZeneca Bolsters Cell Therapy Pipeline With Over $1B Deal For China-Based Gracell Biotechnologies
|
|
Dec 26
|
AstraZeneca set to make one of its first acquisitions in China
|
|
Dec 21
|
Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's Why
|
|
Dec 21
|
Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
|
|
Dec 2
|
Institutions own 19% of Gracell Biotechnologies Inc. (NASDAQ:GRCL) shares but private equity firms control 45% of the company
|
|
Nov 30
|
Is Bausch Health (BHC) Stock Outpacing Its Medical Peers This Year?
|
|
Nov 27
|
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus
|
|
Sep 6
|
Gracell Biotechnologies to Present Updated Clinical Data on BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 2023 International Myeloma Society Annual Meeting
|